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INFLUENCE OF SOME OSTEOTROPIC FACTORS ONMODULATION OF THE
RANKL2 ISOFORM
S. Kwan Tat1, J.-P. Pelletier1, C. Ruiz-Velasco2, M. Padrines2, Y. Fortun2,
F. Mineau1, J. Martel-Pelletier1
1Univ. of Montreal Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada;
2Université de Nantes, Laboratoire de Physiopathologie de la Résorption
Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, France
Purpose: Bone homeostasis is controlled by some members of the TNF
family, of which RANKL is an essential factor for mediating bone resorption.
RANKL exists as three isoforms, RANKL1, 2, and 3, and very little is known
about their regulation and modulation. A recent study by our group on
human normal and osteoarthritic subchondral bone osteoblasts [1] showed
that these cells differentially express membranous RANKL as well as
RANKL1 and RANKL3 isoforms, and that RANKL is differentially regulated
by some osteotropic factors. In that study, speciﬁc human RANKL2 cDNA
primers could not be designed, thus its expression could not be determined.
Here we investigated the RANKL2 protein modulation upon treatment with
the osteotropic factors TNF-α, vitamin D3 and PTH through a mechanistic
model, i.e. human cells that do not constitutively produce RANKL but were
stably transfected with cDNA of the RANKL2 isoform.
Methods: Human embryonic kidney 293 cells, which do not express RANKL,
were stably transfected with the cDNA encoding the transmembranous and
extracellular domain of murine RANKL. Semi-quantitative PCR and Western
Blot were used to determine the level of RANKL2 on the 293 and 293
RANKL2 cells. For the modulation experiments, the 293 RANKL2 cells were
incubated for 72 hours with TNF-α (5 ng/ml), vitamin D3 (50 nM), or
PTH (100 nM). For protein stability determination, cells were pretreated
with or without actinomycin D (5 μg/ml) for 1 hour and then incubated
(0-24 hours) with the above factors with or without actinomycin D. The
production of RANKL2 protein was determined in the cell lysates by a
speciﬁc DUOset ELISA.
Results: Expression and production analyses conﬁrmed that the 293
RANKL2 cells strongly expressed and produced RANKL2. Data showed that
TNF-α signiﬁcantly increased (p<0.03) RANKL2 production, but vitamin D3
and PTH had no effect. Treatment with vitamin D3 and PTH in conjunction
with actinomycin D had no effect on the stability of the RANKL2 protein.
However, TNF-α plus actinomycin D increased the stability of RANKL2
by increasing its half-life, and statistically signiﬁcant difference (p<0.005)
between actinomycin D alone and actinomycin D plus TNF-α was reached
at a 4-hour incubation period.
Conclusions: Our study brings to light that the RANKL2 isoform can be
modulated by TNF-α, a factor highly implicated in some diseases involving
bone resorption and an increase in RANKL activity, such as rheumatoid
arthritis. Interestingly, other osteotropic factors, vitamin D3 and PTH, did
not modulate RANKL2 protein production or its stability/half-life, which
could reﬂect the differential effects of these factors in bone remodelling.
These ﬁndings, in addition to the previous study [1], reveal that all
three RANKL isoforms can be modulated, which strongly suggests that
modulation of a speciﬁc RANKL isoform may be useful for a possible
classiﬁcation of certain osteolytic diseases and/or to assist in identifying
speciﬁc therapeutic treatments.
References
[1] Tat SK, et al. Bone 2008;43:284-91.
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MODULATION OF THE PHENOTYPE OF HUMAN OSTEOARTHRITIC
SUBCHONDRAL OSTEOBLASTS BY CONJUGATED LIPIDS
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Purpose: Altered bone remodeling is important in the initiation of os-
teoarthritis (OA). This may be due to the abnormal phenotype markers and
proliferation of human OA osteoblasts (Ob). The canonical Wnt/β-catenin
signaling pathway is crucial for osteogenesis and we previously demon-
strated that it is reduced in OA. n-3 or n-6 polyunsaturated fatty acids
(PUFAs) affect bone health status and can modify cell markers. Moreover,
recent data suggest bone marrow lesions, which are linked with OA, are
also more prominent in presence of n-6 PUFAs or monounsaturated lipids.
Here we questioned if alterations of lipids in OA Ob could alter their
phenotype, Wnt/β-catenin signaling, and mineralization.
Methods: We prepared primary human subchondral osteoblasts from tibial
plateaus of OA patients undergoing total knee arthroplasty. OA Ob were
incubated for a week in presence of 50 μg/ml of oleate (C18:1), linoleate
(C18:2, n-6 PUFA), linolenate (C18:3, n-3 PUFA), or vehicle. We evaluated
the role of these lipids on alkaline phosphatase and osteocalcin expression
and production, prostaglandin E2 (PGE2) production, and mineralization.
We determined expression of selected genes by qRT-PCR, alkaline phos-
phatase activity by substrate analysis, osteocalcin levels using a selective
EIA, and PGE2 using an ELISA. Wnt3a-dependent Wnt signaling was mea-
sured using the TOPﬂash TCF/lef reporter assay. Mineralization in presence
of the different lipids was assessed by Alizarin red staining in response to
10 ng/ml BMP-2, 10 ng/ml Dexamethasone (Dex), or their combination.
Results: Lipids modiﬁed the expression and production of alkaline phos-
phatase and osteocalcin in OA Ob. Oleate increased alkaline phosphatase
whereas linolenate decreased it. Oleate and linoleate both increased osteo-
calcin release whereas linolenate decreased it as for alkaline phosphatase
activity. Oleate and linoleate both triggered PGE2 production in normal
Ob to levels observed in high OA Ob, and these treatments increased
PGE2 levels in both low and high OA Ob to similar levels. In contrast,
linolenate did not alter PGE2 production by normal and low OA Ob yet
reduced it in high OA Ob. Wnt3a-dependent Wnt signaling remained
similar amongst the different lipid additions. While neither BMP-2 nor Dex
alone modiﬁed signiﬁcantly the mineralization of OA Ob, their combination
enhanced it. Oleate slightly increased the mineralization potential of OA
Ob in presence of BMP-2 and Dex whereas linoleate and linolenate did not
modify signiﬁcantly the response of OA Ob to combined BMP-2 and Dex
treatments.
Conclusions: These results suggest that acute treatment with monounsat-
urated lipids and n-6 PUFAs can exacerbate the altered phenotype of OA
Ob and modify that of normal Ob. Monounsaturated and n-6 PUFAs also
contributed to increase PGE2 production in normal and OA Ob while n-3
PUFAs stabilized PGE2 production. Surprisingly, monounsaturated lipids
could also improve the mineralization potential of OA Ob. In contrast, n-3
PUFAs improved the phenotype of OA Ob while having modest effect on
mineralization. Hence, an altered lipid environment and/or metabolism in
OA bone tissue could contribute to the abnormal phenotype of osteoblasts
and to alter their mineralization capacity.
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ARTICULAR CARTILAGE RESPONSE TO IL-1β IS MODULATED BY THE
UNDERLYING BONE REMODELING ACTIVITY: A NEW DEMONSTRATION OF
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T. Funck-Brentano1 , H. Lin1, M.-D. Ah-Kioon1, R. Nizard2, M.-C. De
Vernejoul1, M. Cohen-Solal1
1INSERM U606, PARIS, France; 2Dept. of orthopeadics, Lariboisière Hosp.,
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Purpose: Osteoarthritis involves cartilage and bone changes although the
role of bone in the pathophysiology is still unclear. We have previously
shown that inhibition of bone resorption had a protective effect on os-
teoarthritis induced in mice with high bone remodelling, suggesting that
level of bone remodelling might inﬂuence cartilage damage. The aim of this
study was to evaluate the effect of bone remodelling activity on cartilage
degradation ex vivo in human explants.
Methods: explants of bone and cartilage were harvested from healthy
zones in patients undergoing total replacement therapy for unicompar-
timental knee OA. Bone and articular cartilage were separated manually
and cultured in parallel in red-phenol-free medium. Bone explants were
cultured BGJb, and cartilage in DMEM. After 24h of stimulation with IL-1β
(10ng/ml), bone explants were cultured in presence of estradiol at 10 or
1000 nM or pamidronate at 1μM for 72h. After changing the medium
for 24h, bone culture supernatant was transferred on cartilage explants
previously stimulated by IL-1β for 24h (ratio 1:3). Control cartilage explants
were cultured with the same ratio of BGJb. Estradiol and pamidronate was
also directly cultured with cartilage explants to test a possible direct effect
of these drugs on cartilage catabolism. Proteoglycan (using the dimethyl-
methylene blue colorimetric assay) and aggrecan neoepitops (by western
blotting (WB) targeting the ARGSV sequence) release in the supernatant
were measured as cartilage catabolism markers.
Results: IL-1β on human cartilage explants induced an increase in proteo-
glycan release (124±2.4% p=0.037) when compared to controls. Supernatant
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of bone explants cultured with estradiol prevented this increase in a dose-
dependent manner (102.5±8.2% at 10nM; 73.4±7.7% at 1000nM; p=0.049)
as well as with pamidronate (79.6±21.8%; p=0.049). The same results were
observed with ARGSV WB with a 41% decrease with estradiol at both doses
and 61% decrease with pamidronate on aggrecanase activity. Direct effect
of estradiol or pamidronate on cartilage explants resulted in a decrease
only with the high dose of estradiol (87.7±24.9%; p=0.049) and with
pamidronate (97.8±8.9%; p=0.049). These results were consistent with data
obtained with ARGSV WB.
Conclusion: These ex vivo results suggest that bone soluble factors are
capable of modulating the remodeling of articular cartilage and indicate the
involvement of catabolic mechanisms. These data provide further evidence
of a cross-talk between bone and cartilage and highlights bone as a
potential target for osteoarthritis therapy.
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EXPRESSION OF THE GROWTH FACTOR PLEIOTROPHIN AND ITS
RECEPTOR PROTEIN TYROSINE PHOSPHATASE BETA/ZETA (RPTPβ/ζ) IN
PATIENTS WITH OSTEOARTHRITIS
A. Kaspiris1, C. Mikelis2, L. Khaldi3, T. Grivas4, I. Kouvaras1, S. Dangas1,
E. Vasileiadis1, E. Papadimitriou2
1Thriasio Gen. Hosp. - NHS, Athens, Greece; 2Lab. of Molecular Pharmacology,
School of Health Sciences, University of Patras, Greece; 3Dept. of
Osteopathology, Lab. for Res. of the Musculoskeletal System, School of
Medicine, University of Athens, Greece; 4Dept. of Trauma and Orthopaedics,
Tzanio General Hospital of Piraeus – NHS, Greece
Purpose: Pleiotrophin (PTN) is a heparin-binding growth factor expressed
in the cartilage in foetal and young age, but its exact role remains unclear
as yet. The purpose of this paper is to study the expression of PTN and its
receptor protein tyrosine phosphatase beta/zeta (RPTPβ/ζ) in the cartilage
and the subchondral bone of patients with osteoarthritis.
Methods: We studied the cartilage and the subchondral bone from 29 pa-
tients who had undergone total knee and hip arthroplasty for osteoarthritis,
by using Western blot and immunohistochemistry analyses. As controls,
we used eight patients operated for fractures of femoral head, who did not
present radiological or macroscopical osteoarthritic changes
Results: PTN and RPTPβ/ζ were not detected in the cartilage of normal
adults. Their expression and interaction were increased in patients with
osteoarthritis (OA) of moderate radiological and histological severity. PTN
was detected mainly in the cytoplasm, in clusters of superﬁcial chondro-
cytes, in necrotic area chondrocytes and in chondrocytes in the tidemark
zone. Moreover, it was also expressed in subchondral bone osteocytes,
with maximum expression in moderate OA. RPTP β/ζ was also found to be
expressed in the subchondral bone in moderate OA, while, as the severity
of the disease increased, it was found to be expressed in the osteocytes of
the trabecular bone.
Conclusions: The increased expression of PTN and RPTPβ/ζ in the cartilage
and subchondral bone of patients with OA renders these molecules poten-
tially interesting candidate targets for developing a therapeutic approach
to the disease
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INHIBITION OF PROSTAGLANDIN E2 AND MATRIX METALLOPROTEINASES
SYNTHESIS IN INTERLEUKIN-1B-STIMULATED OSTEOBLASTS: A
POTENTIAL ROLE OF CHONDROITIN SULFATE ON BONE IN
OSTEOARTHRITIS
E. Pecchi1, S. Priam1, Z. Mladenovic1, M. Gosset1, L. Aguilar2,
F. Berenbaum3, C. Jacques1
1UR 4 - Univ. Pierre et Marie Curie, Paris, France; 2Inst. de recherche Pierre
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Purpose: Osteoarthritis is not only characterized by articular cartilage
destruction but also by an abnormal bone remodeling characterized by
subchondral bone sclerosis and osteophyte formation A growing number
of studies indicate that subchondral bone cells, such as osteoblasts, could
partake in the disease process by releasing mediators involved in articular
cartilage degradation.
Chondroitin sulfate (CS) is a major component of the extracellular matrix
of many connective tissues. This sulfated glycosaminoglycan (GAG), which
is referred as a “symptomatic slow-acting drug in OA” (SySADOA), has been
shown to have anti-inﬂammatory and anti-catabolic properties on chon-
drocytes but little is known about its action on osteoblasts. The objective
of this study was, therefore, to determine the effect of CS on inﬂammatory
mediators and proteolytic enzymes induced by interleukin-1β (IL-1β) and
related to cartilage catabolism in murine osteoblasts.
Methods: Osteoblasts were obtained by enzymatic digestion of calvaria
cortical bone from 5-6-days-old Swiss mice and cultured for 3 weeks as a
primary culture. Cells were then stimulated with 1 or 10 ng/ml of IL-1β
for 24 hours. CS-treated osteoblasts were incubated with 100 μg/ml of CS
during the last week of culture w/o IL-1β. Expressions of cyclooxygenase-2
(COX-2), microsomal prostaglandin E synthase-1 (mPGES-1), 15-hydroxy-
prostaglandin dehydrogenase (15-PGDH), matrix metalloproteinase (MMP)-
3 and -13 were determined by real-time PCR. PGE2 and MMP-3 releases
were analyzed in the medium by enzyme-linked immunosorbent assay.
Results: As expected, IL-1β (at doses of 1 and 10 ng/ml) increased COX-2,
mPGES-1, MMP-3, MMP-13 expression, decreased 15-PGDH expression,
and increased PGE2 and MMP-3 release. Interestingly, CS treatment signiﬁ-
cantly decreased IL-1β-induced expression of COX-2 (by 41% and 65% for
stimulation with 1 ng/ml and 10 ng/ml of IL-1β, respectively), mPGES-1 (by
36% and 55%), MMP-3 (by 25% and 44%) and MMP-13 (by 19% and 49%).
Accordingly, PGE2 and MMP-3 releases were decreased by 57% and 38%
respectively when cells were stimulated with 1 ng/ml of IL-1β, and by 84%
and 50% when cells were stimulated with 10 ng/ml of IL-1β.
Conclusions: Chondroitin sulfate represses the osteoblastic synthesis of
inﬂammatory mediators and proteolytic enzymes involved in cartilage
degradation. These data indicate that the beneﬁcial effects of CS in OA
could not only be due to its action on cartilage but also to its beneﬁcial
effects on subchondral bone.
157
SECRETED FACTORS FROMMATURE OSTEOCLASTS COULD CONTRIBUTE
TO THE PATHOLOGY OF OSTEOARTHRITIS AUGMENTING BONE
FORMATION AND LOWERING CARTILAGE FORMATION
C. Crüger-Hansen, A.V. Neutzky-Wulff, K.V. Andreassen, S.H. Madsen,
M.A. Karsdal, A.-C. Bay-Jensen, K. Henriksen
Nordic BioSci. A/S, Herlev, Denmark
Purpose: Osteoarthritis is a degenerative disease characterized by opposing
processes within cartilage and the subchondral bone: cartilage degradation
and osteosclerosis. Osteoclasts themselves are known to have importance
for the coupling between bone resorption and bone formation, as these
cells secrete factors which induce bone formation. However, it is currently
unknown, whether osteoclasts have direct effects on cartilage turnover. The
aim of this study was to further evaluate the effect of osteoclast secreted
factors on both bone formation and cartilage turnover.
Methods: Human monocytes were isolated from blood and differentiated
into mature osteoclasts using M-CSF and RANKL. Conditioned medium (CM)
and corresponding non-conditioned medium (non-CM) were collected dur-
ing culture. The pre-osteoblastic cell line 2T3 and bovine cartilage explants
were subsequently treated with 50% of CM or non-CM in addition to
relevant controls. Bone formation was assessed by Alizarin Red stain-
ing/dye extraction and cartilage formation was measured by PIINP ELISA.
Cartilage degradation was evaluated by ELISA measurements of both MMP
mediated collagen type II (COL II) degradation and aggrecan cleavage, in
addition to histological evaluations of Safranin-O stained explants following
treatments.
Results: Treatment of 2T3 cells with CM from mature osteoclasts (day
7-10 of culture), strongly induced bone formation by 200%, whereas CM
from monocytes and aged osteoclasts had no bone anabolic effect. CM
from mature osteoclasts, with bone anabolic effect, was furthermore tested
in cartilage explant cultures, where it was demonstrated that cartilage
formation was signiﬁcantly decreased by 70%. In addition, degradation of
aggrecans was increased, measured by both ELISA and histological evalua-
tions. In contrast, MMP mediated degradation of COL II was unchanged.
Conclusions: Osteoclasts with a speciﬁc maturity have the ability to
stimulate bone formation by secretion of bone anabolic signals. However,
the same CM had opposite effects on cartilage, namely reduced formation
and accelerated aggrecan degradation. All together, these data point in
the direction of osteoclasts having important roles, for both bone and
cartilage turnover. These observations could be of speciﬁc relevance for
osteoarthritis pathology, in which cartilage catabolic and bone anabolic
processes are taking place at the same time.
